公开(公告)号：WO2007064978A2

公开(公告)日：2007-06-07

申请号：PCT/US2006/046159

申请日：2006-11-30

Applicant: CELATOR PHARMACEUTICALLS, INC. ,  MAYER, Lawrence

Inventor： MAYER, Lawrence

IPC: A61F2/02

CPC classification number: A61L31/16 ,  A61L31/10 ,  A61L2300/61

Abstract: Implants comprising controlled delivery matrices, associated with, or including medical devices, having stably and releasably associated therewith predetermined non- antagonistic combinations of two or more therapeutic agents provide control of the ratio of these agents at a localized site. Methods of identifying such combinations are also disclosed.

Abstract translation: 包含受控递送基质的植入物，与或具有医疗装置相关联或包含医疗装置的植入物，其具有稳定和可释放地与两种或更多种治疗剂的预定非拮抗性组合相关联，提供了这些药剂在局部位点处的比率的控制。 还公开了鉴定这种组合的方法。

公开(公告)号：WO2009070761A1

公开(公告)日：2009-06-04

申请号：PCT/US2008/085030

申请日：2008-11-26

Applicant: CELATOR PHARMACEUTICALS, INC ,  ANSELL, Steven, M. ,  JOHNSTONE, Sharon ,  TARDI, Paul ,  MAYER, Lawrence

Inventor： ANSELL, Steven, M. ,  JOHNSTONE, Sharon ,  TARDI, Paul ,  MAYER, Lawrence

IPC: A61K9/127

CPC classification number: A61K9/1075 ,  A61K9/5123 ,  A61K9/5146 ,  A61K31/337 ,  A61K47/543 ,  C07D305/14

Abstract: Nanoparticulate formulations for delivery of taxane conjugate prodrug formed from a taxane coupled to a hydrophobic moiety through a glycolate linker are described.

Abstract translation: 描述了通过乙醇酸酯连接体与通过疏水部分偶联的紫杉烷形成的用于递送紫杉烷结合物前药的纳米颗粒制剂。

公开(公告)号：WO2010043050A1

公开(公告)日：2010-04-22

申请号：PCT/CA2009/001483

申请日：2009-10-16

Applicant: CELATOR PHARMACEUTICALS CORPORATION ,  TARDI, Paul ,  MAYER, Lawrence ,  BERMUDES, David

Inventor： TARDI, Paul ,  MAYER, Lawrence ,  BERMUDES, David

IPC: A61K31/4745 ,  A61K31/496 ,  A61K31/513 ,  A61K31/7072 ,  A61K39/395 ,  A61K9/127 ,  A61P35/00

CPC classification number: A61K9/127 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/513 ,  A61K31/7072 ,  A61K39/39558 ,  A61K2300/00

Abstract: Compositions which comprise a liposomal water-soluble camptothecin and optionally a liposomal fluoropyrimidine in combination with a vascular epithelial growth factor (VEGF) inhibitor such as cetuximab or an epidermal growth factor receptor (EGFR) inhibitor such as bevacizumab are useful in achieving enhanced therapeutic effects for the treatment of cancer.

Abstract translation: 包含脂质体水溶性喜树碱和任选的脂质体氟嘧啶与血管上皮生长因子（VEGF）抑制剂如西妥昔单抗或表皮生长因子受体（EGFR）抑制剂如贝伐单抗联合的组合物可用于实现增强的治疗效果 治疗癌症。

公开(公告)号：WO2009097011A1

公开(公告)日：2009-08-06

申请号：PCT/US2008/073185

申请日：2008-08-14

Applicant: CELATOR PHARMACEUTICALS, INC. ,  TARDI, Paul ,  JOHNSTONE, Sharon ,  MAYER, Lawrence

Inventor： TARDI, Paul ,  JOHNSTONE, Sharon ,  MAYER, Lawrence

IPC: A61K9/127

CPC classification number: A61K9/127 ,  A61K9/0019 ,  A61K31/4745 ,  A61K31/555 ,  A61K33/24

Abstract: Compositions which comprise liposomes having controlled release of a platinum agent are useful in achieving enhanced therapeutic effects particularly when these drugs are administered in combination with other therapeutic agents.

Abstract translation: 包含具有铂剂的受控释放的脂质体的组合物可用于实现增强的治疗效果，特别是当这些药物与其它治疗剂组合施用时。

公开(公告)号：WO2007035783A2

公开(公告)日：2007-03-29

申请号：PCT/US2006/036569

申请日：2006-09-19

Applicant: CELATOR PHARMACEUTICALS, INC. ,  JOHNSTONE, Sharon ,  HARVIE, Pierrot ,  TARDI, Paul ,  HARASYM, Troy ,  MAYER, Lawrence

Inventor： JOHNSTONE, Sharon ,  HARVIE, Pierrot ,  TARDI, Paul ,  HARASYM, Troy ,  MAYER, Lawrence

IPC: A61K9/127

CPC classification number: A61K9/127

Abstract: Compositions which comprise delivery vehicles having stably associated therewith a cytidine analog and a platinum agent are useful in achieving enhanced therapeutic effects when combinations of these drugs are administered.

Abstract translation: 包含稳定与胞苷类似物和铂剂相关的递送载体的组合物在施用这些药物的组合时可用于实现增强的治疗效果。

公开(公告)号：WO2006081354A3

公开(公告)日：2006-08-03

申请号：PCT/US2006/002782

申请日：2006-01-26

Applicant: CELATOR PHARMACEUTICALS, INC. ,  TARDI, Paul ,  MAYER, Lawrence ,  CABRAL-LILLY, Donna

Inventor： TARDI, Paul ,  MAYER, Lawrence ,  CABRAL-LILLY, Donna

IPC: A61K9/127

Abstract: The invention relates to a method for reducing the polydispersity of a population of gel-phase lipid-based delivery vehicles.

公开(公告)号：WO2007076117A2

公开(公告)日：2007-07-05

申请号：PCT/US2006/049245

申请日：2006-12-22

Applicant: CELATOR PHARMACEUTICALS, INC. ,  DICKO, Awa ,  TARDI, Paul ,  MAYER, Lawrence ,  JOHNSTONE, Sharon

Inventor： DICKO, Awa ,  TARDI, Paul ,  MAYER, Lawrence ,  JOHNSTONE, Sharon

IPC: C12Q1/68

CPC classification number: A61K9/1278

Abstract: Provided herein are liposomal compositions comprising a therapeutic agent having a protonatable amino group and a secondary or tertiary amine, and methods for encapsulating such therapeutic agents. In one aspect, the present invention relates to liposomal formulations comprising irinotecan in a triethanolamine solution, and optionally comprising copper gluconate, and methods for preparing the same.

Abstract translation: 本文提供了包含具有可质子化氨基和仲胺或叔胺的治疗剂的脂质体组合物，以及用于包封这些治疗剂的方法。 在一个方面，本发明涉及包含伊立替康在三乙醇胺溶液中并且任选地包含葡糖酸铜的脂质体制剂及其制备方法。

公开(公告)号：WO2007050784A2

公开(公告)日：2007-05-03

申请号：PCT/US2006/041832

申请日：2006-10-25

Applicant: CELATOR PHARMACEUTICALS, INC. ,  BATIST, Gerald ,  MAYER, Lawrence ,  SWENSON, Christine ,  JANOFF, Andrew ,  GELMON, Karen

Inventor： BATIST, Gerald ,  MAYER, Lawrence ,  SWENSON, Christine ,  JANOFF, Andrew ,  GELMON, Karen

IPC: A61K31/4745 ,  A61K31/505 ,  A61P35/00

CPC classification number: A61K31/4745 ,  A61K31/505

Abstract: Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine. Such methods are particularly useful in the treatment of cancer patients with advanced solid tumors.

Abstract translation: 本文提供了通过施用包含固定的，非拮抗摩尔比的伊立替康和氟尿苷的药物组合物来治疗癌症的方法。 这些方法特别可用于治疗晚期实体瘤的癌症患者。

公开(公告)号：WO2006055903A1

公开(公告)日：2006-05-26

申请号：PCT/US2005/042131

申请日：2005-11-18

Applicant: CELATOR PHARMACEUTICALS, INC. ,  TARDI, Paul ,  WEBB, Murray ,  JOHNSTONE, Sharon ,  HARVIE, Pierrot ,  MAYER, Lawrence

Inventor： TARDI, Paul ,  WEBB, Murray ,  JOHNSTONE, Sharon ,  HARVIE, Pierrot ,  MAYER, Lawrence

IPC: A61K9/127

CPC classification number: A61K9/127 ,  A61K9/1278

Abstract: This invention relates to encapsulation of drugs and other agents into preformed delivery vehicles.

Abstract translation: 本发明涉及将药物和其他药剂包封到预先形成的运载工具中。

公开(公告)号：WO2004087115A3

公开(公告)日：2004-10-14

申请号：PCT/CA2004/000507

申请日：2004-04-02

Applicant: CELATOR TECHNOLOGIES INC. ,  MAYER, Lawrence ,  BALLY, Marcel ,  WEBB, Murray ,  TARDI, Paul ,  JOHNSTONE, Sharon

Inventor： MAYER, Lawrence ,  BALLY, Marcel ,  WEBB, Murray ,  TARDI, Paul ,  JOHNSTONE, Sharon

IPC: A61K9/127

Abstract: Compositions which comprise liposomes having stably associated therewith a camptothecin and a fluoropyrimidine are useful in achieving enhanced therapeutic effects when combinations of these drugs are administered.